Published date: Jun 28 2024

Journal Title: West Kazakhstan Medical Journal

Issue title: West Kazakhstan Medical Journal: Volume 66 Issue 2

Pages: 106–110

DOI: 10.18502/wkmj.v66i2.16452

Asset A. Kaliyevaset_kaliyev@mail.ruDepartment of General Surgery, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

Nadiar M. MussinDepartment of General Surgery, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

Amin TamadonDepartment for Scientific Work, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

Mesenchymal stromal/stem cell (MSC) therapy has emerged as a transformative strategy in cancer treatment, leveraging the unique regenerative and immunomodulatory properties of MSCs to address the limitations of traditional approaches. This comprehensive review delves into the multifaceted applications and intricate mechanisms of action underlying MSC therapy for cancer. MSCs exhibit remarkable tumor-targeting capabilities, harnessing their innate homing abilities for selective migration to tumor sites. This property is harnessed for targeted drug delivery, optimizing therapeutic efficacy while minimizing collateral damage to healthy tissues. Moreover, the immunomodulatory prowess of MSCs plays a pivotal role in shaping the tumor microenvironment. Through the suppression of pro-inflammatory signals and the promotion of antitumor immune responses, MSCs create a milieu that inhibits tumor growth. Engineered MSCs further serve as carriers for anticancer drugs, facilitating direct delivery to tumor sites and mitigating systemic toxicity. Additionally, the radioprotective effects of MSCs provide a unique opportunity to enhance the therapeutic window during radiotherapy, safeguarding healthy tissues. However, challenges such as achieving consistent tumor tropism, addressing safety concerns, and standardizing protocols underscore the need for ongoing research. Rigorous clinical trials are imperative to establish the safety profile and efficacy of MSC therapy across diverse cancer types. As we navigate these challenges, the promise of personalized and effective cancer treatments through MSC therapy continues to unfold, offering new hope for improved outcomes in the relentless battle against cancer.

Keywords: mesenchymal stromal/stem cells (MSCs), cancer therapy, tumor targeting, immunomodulation, drug delivery

[1] Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience 2019;13: 961. doi: 10.3332/ecancer.2019.961

[2] Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V. Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol 2020; 8:43. doi: 10.3389/fbioe.2020.00043

[3] Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 2016;7: e2062, doi: 10.1038/cddis.2015.327

[4] Cheng S, Nethi SK, Rathi S, Layek B, Prabha S. Engineered mesenchymal stem cells for targeting solid tumors: Therapeutic potential beyond regenerative therapy. J Pharmacol Exp Ther 370 (2019) 231-41, doi: 10.1124/jpet.119.259796

[5] Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z, et al. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics (2023;15: 2233, doi: 10.3390/pharmaceutics15092233

[6] Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006;13:419-25, doi: 10.1097/01.moh.0000245697.54887.6f

[7] Rivera-Cruz CM, Shearer JJ, Figueiredo Neto M, Figueiredo ML. The immunomodulatory effects of mesenchymal stem cell polarization within the tumor microenvironment niche. Stem Cells Int. 2017;doi: 10.1155/2017/4015039

[8] Su Y, Zhang T, Huang T, Gao J. Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements. Int J Pharm. 2021;600: doi: 10.1016/j.ijpharm.2021.120477

[9] Almeida-Porada G, Atala AJ, Porada CD. Therapeutic mesenchymal stromal cells for immunotherapy and for gene and drug delivery. Mol Ther Methods Clin Dev. 2020;16:204-24, doi: 10.1016/j.omtm.2020.01.005

[10] Yu H, Yang Z, Li F, Xu L, Sun Y. Cell-mediated targeting drugs delivery systems. Drug Deliv.2020;27: 1425-37, doi: 10.1080/10717544.2020.1831103

[11] Yeom J, Kim SJ, Jung H, Namkoong H, Yang J, Hwang BW, et al. Supramolecular hydrogels for long-term bioengineered stem cell therapy. Advanced Healthcare Materials. 2025;4:237-44, doi: 10.1002/adhm.201400304

[12] Papait A, Stefani FR, Cargnoni A, Magatti M, Parolini O, Silini AR. The multifaceted roles of MSCs in the tumor microenvironment: Interactions with immune cells and exploitation for therapy. Front Cell Dev Biol. 2020;8:447, doi: 10.3389/fcell.2020.00447

[13] Xuan X, Tian C, Zhao M, Sun Y, Huang C. Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance. Cancer Cell Int. 2021;21: 595, doi: 10.1186/s12935-021-02300-4

[14] Li P, Ou Q, Shi S, Shao C. Immunomodulatory properties of mesenchymal stem cells/dental stem cells and their therapeutic applications. Cell Mol Immunol. 2023;20:558-69, doi: 10.1038/s41423-023- 00998-y

[15] Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted drug delivery - from magic bullet to nanomedicine: Principles, challenges, and future perspectives. J Multidiscip Healthc. 2021;14:1711-24, doi: 10.2147/JMDH.S313968

[16] Nicolay NH, Lopez Perez R, Saffrich R, Huber PE. Radio-resistant mesenchymal stem cells: Mechanisms of resistance and potential implications for the clinic. Oncotarget. 2015;6: 19366-80, doi: 10.18632/oncotarget.4358

[17] Reda M, Bagley AF, Zaidan HY, Yantasee W. Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials. Radiother Oncol. 2020;150: 225-35, doi: 10.1016/j.radonc.2020.06.041

[18] Alvites R, Branquinho M, Sousa AC, Lopes B, Sousa P, Mauricio AC. Mesenchymal stem/stromal cells and their paracrine activity-immunomodulation mechanisms and how to influence the therapeutic potential. Pharmaceutics.= 2022;14:381, doi: 10.3390/pharmaceutics14020381

[19] Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41:653-64, doi: 10.1016/j.tips.2020.06.009

[20] Chhabra G, Singh CK, Amiri D, Akula N, Ahmad N. Recent advancements on immunomodulatory mechanisms of resveratrol in tumor microenvironment. Molecules. 2021;26:1343, doi: 10.3390/molecules26051343

[21] Vasanthan J, Gurusamy N, Rajasingh S, Sigamani V, Kirankumar S, Thomas EL, et al. Role of human mesenchymal stem cells in regenerative therapy. Cells. 2020;10:54, doi: 10.3390/cells10010054